Clinical Trials Browser

Phase 4 × OTHER_GOV × Bortezomib × Clear all

NCT05137860 2022-01-18

Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD

Phase 4 Unknown

LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02773550 2020-01-18

Velcadito

Phase 4 Terminated

Multiple Myeloma